OTC · PURE
Consumer Defensive · Household & Personal Products
$0.07
Down-$0.01 (-7.14%)
Updated Nov 5, 2026, 2:38 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PURE
1M range · 0 trading sessions · Daily adjusted prices
PURE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning PURE.
Company
Market Activity
Research & News
PURE research
Company profile and research snapshot.
PURE BIOSCIENCE
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 29, 2026
EL CAJON, Calif., October 29, 2026--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company," or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2026.
Benzinga · Oct 29, 2026
PURE Bioscience (OTC:PURE) reported $662.000 thousand in sales this quarter. This is a 13.35 percent decrease over sales of $764.000 thousand the same period last year.
Benzinga · Jun 15, 2026
PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $506.000 thousand in sales this quarter. This is a 3.05 percent increase
Benzinga · Mar 16, 2026
PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $443.000 thousand in sales this quarter. This is a 13.30 percent increase
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PURE.
